Editorial Comment to Utility of whole‐body diffusion‐weighted magnetic resonance imaging in the management of treatment‐related neuroendocrine prostate cancer

Abstract

imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat. Med. 2004; 22: 275–82. 6 Padhani AR, Lecouvet FE, Tunariu N et al. Rationale for modernising imaging in advanced prostate cancer. Eur. Urol. Focus. 2017; 3: 223–39. 7 Lecouvet FE, Talbot JN, Messiou C et al. Monitoring the response of bone metastases to treatment with magnetic resonance imaging and nuclear medicine techniques: a review and position statement by the European Organisation for Research and Treatment of Cancer imaging group. Eur. J. Cancer 2014; 50: 2519–31. 8 Soloway MS, Hardeman SW, Hickey D et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988; 61: 195–202. 9 Wang HT, Yao YH, Li BG et al. Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis. J. Clin. Oncol. 2014; 32: 3383–90. 10 Fl echon A, Pouessel D, Ferlay C et al. Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial. Ann. Oncol. 2011; 22: 2476–81. 11 Klenk C, Gawande R, Uslu L et al. Ionising radiation-free whole-body MRI versus (18)F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study. Lancet Oncol. 2014; 15: 275–85. 12 Wilhelm T, Stieltjes B, Schlemmer HP. Whole-body-MR-diffusion weighted imaging in oncology. Rofo 2013; 184: 950–8. 13 Xu GZ, Li CY, Zhao L et al. Comparison of FDG whole-body PET/CT and gadolinium-enhanced whole-body MRI for distant malignancies in patients with malignant tumors: a meta-analysis. Ann. Oncol. 2013; 24: 96–101. 14 Blackledge MD, Collins DJ, Tunariu N et al. Assessment of treatment response by total tumor volume and global apparent diffusion coefficient using diffusion-weighted MRI in patients with metastatic bone disease: a feasibility study. PLoS One 2014; 9: e91779. 15 Spratt DE, Gavane S, Tarlinton L et al. Utility of FDG-PET in clinical neuroendocrine prostate cancer. Prostate 2014; 74: 1153–9. 16 Sterzing F, Kratochwil C, Fiedler H et al. (68)Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients. Eur. J. Nucl. Med. Mol. Imaging 2016; 43: 34–41. 17 Parida GK, Tripathy S, Datta Gupta S et al. Adenocarcinoma prostate with neuroendocrine differentiation: potential utility of 18F-FDG PET/CT and 68Ga-DOTANOC PET/CT over 68Ga-PSMA PET/CT. Clin. Nucl. Med. 2018; 43: 248–9.